Use of Texaphyrin in ocular diagnosis and therapy

A method for observing vasculature in an eye of a subject, the method comprising:

• administering a detectable texaphyrin to the subject;
• and
• observing the vasculature of the eye
• wherein the detectable texaphyrin has structure I:
• or structure II:
• wherein
• M is a diamagnetic metal cation;
• R1-R4, R7 and R8 are independently hydrogen, halide, hydroxyl, alkyl, alkenyl, alkynyl, aryl, haloalkyl, nitro, formyl, acyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, saccharide, carboxy, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, a site-directing molecule, a catalytic group, or a linker that is linked to a site-directing molecule or to a catalytic group;
• R6 and R9 are independently selected from the groups of R1-R4, R7 and R8, with the proviso that the halide is other than iodide and the haloalkyl is other than iodoalkyl;
• R5 and R10-R12 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, or a linker that is linked to a saccharide, to a site-directing molecule, or to a catalytic group;
• R13 is alkyl, alkenyl, oxyalkyl, or hydroxyalkyl having up to about 3 carbon atoms and having rotational flexibility around a first-bound carbon atom;
• and
• n is an integer value less than or equal to 5.

A method for observing and treating an ocular condition characterized by abnormal vasculature of a subject using a single agent, the method comprising

• administering a photosensitive fluorescent texaphyrin to the subject;
• observing the ocular condition of the subject by fluorescence of the texaphyrin;
• and
• photoirradiating the vasculature
• wherein the texaphyrin has structure I:
• or structure II:
• wherein
• M is a diamagnetic metal cation;
• R1-R4, R7 and R8 are independently hydrogen, halide, hydroxyl, alkyl, alkenyl, alkynyl, aryl, haloalkyl, nitro, formyl, acyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, saccharide, carboxy, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, a site-directing molecule, a catalytic group, or a linker that is linked to a site-directing molecule or to a catalytic group;
• R6 and R9 are independently selected from the groups of R1-R4, R7 and R8, with the proviso that the halide is other than iodide and the haloalkyl is other than iodoalkyl;
• R5 and R10-R12 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, or a linker that is linked to a saccharide, to a site-directing molecule, or to a catalytic group;
• R13 is alkyl, alkenyl, oxyalkyl, or hydroxyalkyl having up to about 3 carbon atoms and having rotational flexibility around a first-bound carbon atom;
• and
• n is an integer value less than or equal to 5.

A method for photodynamic therapy of macular degeneration of a subject comprising:

• administering a photosensitive texaphyrin to the subject where the photosensitive texaphyrin has structure I:
• or structure II:
• wherein
• M is a diamagnetic metal cation;
• R1-R4, R7 and R8 are independently hydrogen, halide, hydroxyl, alkyl, alkenyl, alkynyl, aryl, haloalkyl, nitro, formyl, acyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, saccharide, carboxy, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, a site-directing molecule, a catalytic group, or a linker that is linked to a site-directing molecule or to a catalytic group;
• R6 and R9 are independently selected from the groups of R1-R4, R7 and R8, with the proviso that the halide is other than iodide and the haloalkyl is other than iodoalkyl;
• R5 and R10-R12 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, or a linker that is linked to a saccharide, to a site-directing molecule, or to a catalytic group;
• R13 is alkyl, alkenyl, oxyalkyl, or hydroxyalkyl having up to about 3 carbon atoms and having rotational flexibility around a first-bound carbon atom;
• and
• n is an integer value less than or equal to 5 and
• photoirradiating the macula.